# Resource Summary Report

Generated by dkNET on Sep 7, 2026

## HuCC-T1

RRID:CVCL_0324
Type: Cell Line

### Proper Citation

RRID:CVCL_0324

### Cell Line Information

**URL:** https://web.expasy.org/cellosaurus/CVCL_0324

**Proper Citation:** RRID:CVCL_0324

**Description:** Cell line HuCC-T1 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Male

**Disease:** Intrahepatic cholangiocarcinoma

**Defining Citation:** PMID:2544546, PMID:9290701, PMID:20164919, PMID:20215515, PMID:21451941, PMID:21687941, PMID:22460905, PMID:25877200, PMID:26956050, PMID:27231123, PMID:27397505, PMID:30894373, PMID:31068700, PMID:31077409, PMID:31395879, PMID:32899426, PMID:35640676, PMID:35839778, PMID:39026794

**Comments:** Population: Japanese., Part of: TCGA-110-CL cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: Biliary tract cancer cell line atlas.

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** HuCC-T1

**Synonyms:** HuCCT-1, HUCCT-1, HUCC-T1, HUCCT1, HuCCT1, HuccT1

**Cross References:** BTO:BTO_0003911, CLO:CLO_0050009, MCCL:MCC:0000217, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioSample:SAMN01821687, BioSample:SAMN03470954, BioSample:SAMN03471627, BioSample:SAMN10987837, cancercelllines:CVCL_0324, CCRID:5301HUM-KCB21005YJ, Cell_Model_Passport:SIDM00587, ChEMBL-Cells:CHEMBL3307409, ChEMBL-Targets:CHEMBL614581, CLS:300469, Cosmic:907069, Cosmic:1122350,

Cosmic:1571782, Cosmic:2009540, Cosmic:2629288, Cosmic:2674063, Cosmic-CLP:907069, DepMap:ACH-000976, EGA:EGAS00001000978, FANTOM5_SSTAR:10432-106D9, GDSC:907069, GEO:GSM827224, GEO:GSM887144, GEO:GSM888216, GEO:GSM1669917, IARC_TP53:21387, JCRB:JCRB0425, KCB:KCB 202105YJ, LiGeA:CCLE_833, LINCS_LDP:LCL-1788, PharmacoDB:HuCCT1_635_2019, PRIDE:PXD030304, PRIDE:PXD033685, Progenetix:CVCL_0324, PubChem_Cell_line:CVCL_0324, RCB:RCB1960, TKG:TKG 0389, Wikidata:Q54896725

**ID:** CVCL_0324

**Record Creation Time:** 20220427T220620+0000

**Record Last Update:** 20260905T180816+0000

## Ratings and Alerts

No rating or validation information has been found for HuCC-T1.

No alerts have been found for HuCC-T1.

## Data and Source Information

**Source:** Cellosaurus

## Usage and Citation Metrics

We found 375 mentions in open access literature.

**Listed below are recent publications.** The full list is available at dkNET .

Zhou Y, et al. (2026) FXYD3 Promotes Tumor Progression by Binding With IRF7 to Regulate JAK2/STAT5 Signaling in Intrahepatic Cholangiocarcinoma. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(3), e10782.

Liu Y, et al. (2026) Detection of circulating tumor cells in cholangiocarcinoma via epithelial-mesenchymal transition markers and their application. iScience, 29(4), 115451.

Zhong Y, et al. (2026) HERV2365 upregulates FGF1 expression by sponging miR-326 to promote the progression of intrahepatic cholangiocarcinoma. iScience, 29(6), 115852.

Li X, et al. (2026) LFPM inhibition of RING1-mediated p53R175H degradation drives oncogenesis in p53R175H-mutant cancers. Cell death and differentiation.

Luo L, et al. (2026) Targeting m6A Reader YTHDF1 Enhances Antitumor Immunity and Potentiates Anti-PD-L1 Efficacy in Intrahepatic Cholangiocarcinoma. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(32), e20403.

Liu CT, et al. (2026) Mutant Isocitrate Dehydrogenase 1 Sensitizes Intrahepatic Cholangiocarcinoma Cells to MDM2 Inhibitors. Cancer research communications, 6(3), 616.

Lin Y, et al. (2026) Robust transcriptomic hallmarks targeting intratumor heterogeneity in intrahepatic cholangiocarcinoma. Cell reports. Medicine, 7(4), 102708.

Entrialgo-Cadierno R, et al. (2026) Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma. Cancer cell, 44(6), 1218.

Wang F, et al. (2026) MYC-Mediated Functional Manifestation of IDH1 Mutations in Intrahepatic Cholangiocarcinoma Confers Sensitivity to (+)-JQ1. International journal of biological sciences, 22(5), 2247.

Cai D, et al. (2026) L-lactate-driven PSMD14 lactylation and stabilization promote lactate production and ferroptosis resistance via ENO1 in intrahepatic cholangiocarcinoma. Cancer letters, 646, 218394.

Taguchi D, et al. (2025) Dual Roles of Canagliflozin on Cholangiocarcinoma Cell Growth and Enhanced Growth Suppression in Combination with FK866. International journal of molecular sciences, 26(3).

Zhao CH, et al. (2025) Idarubicin-transarterial chemoembolization combined with gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma. World journal of gastrointestinal oncology, 17(4), 103776.

Luo G, et al. (2025) Platelets promote metastasis of intrahepatic cholangiocarcinoma through activation of TGF-??/Smad2 pathway. Biochimica et biophysica acta. Molecular basis of disease, 1871(4), 167734.

Yuan WC, et al. (2025) HBO1 functions as an epigenetic barrier to hepatocyte plasticity and reprogramming during liver injury. Cell stem cell, 32(6), 990.

Inthanachai T, et al. (2025) Novel B7-H3 CAR T cells show potent antitumor effects in glioblastoma: a preclinical study. Journal for immunotherapy of cancer, 13(1).

Myint KZ, et al. (2024) Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation. Pharmaceuticals (Basel, Switzerland), 17(2).

Chen T, et al. (2024) S100A6 drives lymphatic metastasis of liver cancer via activation of the RAGE/NF-kB/VEGF-D pathway. Cancer letters, 587, 216709.

Bekric D, et al. (2024) The efficacy of ferroptosis-inducing compounds IKE and RSL3 correlates with the expression of ferroptotic pathway regulators CD71 and SLC7A11 in biliary tract cancer cells. PloS one, 19(4), e0302050.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell chemical biology, 31(7), 1247.

Alva-Ruiz R, et al. (2024) YAP-TEAD inhibition is associated with upregulation of an androgen receptor mediated transcription program providing therapeutic escape. FEBS open bio, 14(11), 1873.